Welcome to visit Zhongnan Medical Journal Press Series journal website!

A case report of cardiorenal syndrome accompany with cardiogenic cirrhosis and scrotal edema

Published on Nov. 08, 2021Total Views: 4141 timesTotal Downloads: 2550 timesDownloadMobile

Author: Jie CHENG 1, 2, 3 Qian WANG 1, 2, 3 Zi-Ang LI 1, 2, 3 Yao-Jia LAO 1, 2, 3 Kai HUANG 1, 2, 3 Juan-Li MOU 1, 2, 3 Jun LIN 1, 2, 3

Affiliation: 1. Department of Gastroenterology, Zhongnan hospital of Wuhan University, Wuhan 430071, China 2. The Hubei Clinical Center & Key Laboratory of Intestinal & Colorectal Diseases, Wuhan 430071, China 3. Hubei Key Laboratory of Intestinal and Colorectal Diseases, Wuhan 430071, China

Keywords: Cardiorenal syndrome Cirrhosis Scrotal edema Blood purification

DOI: 10.12173/j.issn.1004-5511.202104032

Reference: Cheng J, Wang Q, Li ZA, Lao YJ, Huang K, Mou JL, Lin J. A case report of cardiorenal syndrome accompany with cardiogenic cirrhosis and scrotal edema[J]. Yixue Xinzhi Zazhi, 2021, 31(6): 478-482. DOI: 10.12173/j.issn.1004-5511.202104032.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Cardiorenal syndrome (CRS) is a vicious circle caused by the interaction between heart failure and kidney disease having a poor prognosis. We have reviewed a case of a patient with rheumatic heart disease valve replacement and repair surgery, diagnosed on admission as having CRS, combined with cardiogenic liver cirrhosis and severe scrotal edema. He was discharged after repeated blood puri-fication treatments. The patient died within the three months following after discharge. It is suggested that for patients with CRS and cardiogenic liver cirrhosis for whom surgery is no longer an option, the short-term effect of blood purification treatment is acceptable, however the long-term prognosis still needs more case observation.

Full-text
Please download the PDF version to read the full text: download
References

1. Uduman J. Epidemiology of cardiorenal syndrome[J]. Adv Chronic Kidney Dis, 2018, 25(5): 391-399. DOI: 10.1053/j.ackd.2018.08.009. 

2. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus confer-ence of the acute dialysis quality initiative[J]. Eur Heart J, 2010, 31(6): 703-711. DOI: 10.1093/eurheartj/ehp507.

3. Zhang Y, Jiang Y, Yang W, et al. Chronic secondary cardiorenal syndrome: the sixth innovative sub-type[J]. Front Cardiovasc Med, 2021, 8: 639959. DOI: 10.3389/fcvm.2021.639959.

4. Haase M, Müller C, Damman K, et al. Pathogenesis of cardiorenal syndrome type 1 in acute decom-pensated heart failure: workgroup statements from the eleventh consensus conference of the acute dialysis quality initiative (ADQI) [J]. Contrib Nephrol, 2013, 182: 99-116. DOI: 10.1159/000349969.

5. Vandenberghe W, Gevaert S, Kellum JA, et al. Acute kidney injury in cardiorenal syndrome type 1 pa-tients: a systematic review and meta-analysis[J]. Cardiorenal Med, 2016, 6(2): 116-128. DOI: 10.1159/000442300.

6. Zannad F, Rossignol P. Cardiorenal syndrome revisited[J]. Circulation, 2018, 138(9): 929-944. DOI: 10.1161/CIR CULATIONAHA.117.028814.

7. Wang J, Zhang W, Wu L, et al. New insights into the pathophysiological mechanisms underlying cardi-orenal syndrome[J]. Aging (Albany NY), 2020, 12(12): 12422-12431. DOI: 10.18632/aging.103354.

8. Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: charac-terization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.

9. Kazory A, Ronco C. Hepatorenal syndrome or hepatocardiorenal syndrome: revisiting basic concepts in view of emerging data[J]. Cardiorenal Med, 2019, 9(1): 1-7. DOI: 10.1159/000492791.

10.  Xanthopoulos A, Starling RC, Kitai T, et al. Heart failure and liver disease: cardiohepatic interactions[J]. JACC Heart Fail, 2019, 7(2): 87-97. DOI: 10.1016/j.jchf.2018.10.007.

11.  Møller S, Bernardi M. Interactions of the heart and the liver[J]. Eur Heart J, 2013, 34(36): 2804-2811. DOI: 10.1093/eurheartj/eht246.

12.  Kazory A, Costanzo MR. Extracorporeal isolated ultrafiltration for management of congestion in heart failure and cardiorenal syndrome[J]. Adv Chronic Kidney Dis, 2018, 25(5): 434-442. DOI: 10.1053/j.ackd.2018.08.007.

13.  Oda S, Sadahiro T, Hirayama Y, et al. Non-renal indications for continuous renal replacement therapy: current status in Japan[J]. Contrib Nephrol, 2010, 166: 47-53. DOI: 10.1159/000314851.

14.  Schwenger V, Remppis AB. Renal replacement therapy for refractory heart failure[J]. Der Internist, 2012, 53(7): 823-832. DOI: 10.1007/s00108-011-3009-y.

15.  Jentzer JC, Bihorac A, Brusca SB, et al. Contemporary management of severe acute kidney injury and refractory cardiorenal syndrome: JACC council perspectives[J]. J Am Coll Cardiol, 2020, 76(9): 1084-1101. DOI: 10.1016/j.jacc.2020.06.070.

16.  Costanzo MR, Ronco C, Abraham WT, et al. Extracorporeal ultrafiltration for fluid overload in heart failure: current status and prospects for further research[J]. J Am Coll Cardiol, 2017, 69(19): 2428-2445. DOI: 10.1016/j.jacc. 2017.03.528.

17.  Augustyn A, Peng L, Singal AG, et al. Surveillance for hepatocellular carcinoma secondary to cardio-genic cirrhosis in patients with congenital heart disease[J]. Clin Res Cardiol, 2015, 104(5):446-449. DOI: 10.1007/s00392-015-0809-4.